CLI
-
Fully funded with strong IP Portfolio, Hemostemix marches forward towards FDA Phase II Clinical Trial Completion
Hemostemix Inc. (TSXV: HEM | OTC: HMTXF) continues to move forward with its FDA Phase II clinical trial…
-
Hemostemix steps into the new year with capital and its critical clinical study data in hand
With a new management team spearheading Hemostemix Inc. (TSXV: HEM | OTC: HMTXF), the Company started 2021 with…
